Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era

Area of Science:

• Public Health
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Multidrug-resistant tuberculosis (MDR-TB) is a significant global health challenge, contributing substantially to deaths from antimicrobial resistance.
• Individuals with MDR-TB infection face a high risk of developing active TB disease, necessitating preventive strategies.
• There has been a lack of randomized evidence to guide the development of TB preventive treatment guidelines for MDR-TB.

Purpose of the Study:

• To provide randomized evidence on the efficacy and safety of levofloxacin for preventing TB disease in household contacts exposed to MDR-TB.
• To inform updated World Health Organization (WHO) guidelines for TB preventive treatment.

Main Methods:

• Two recently completed randomized controlled trials were analyzed.
• The trials evaluated the safety and efficacy of daily levofloxacin administered for six months to household contacts of patients with MDR-TB.

Main Results:

• The six-month daily levofloxacin regimen was found to be safe and efficacious in preventing TB disease among MDR-TB exposed contacts.
• These findings represent the first randomized evidence supporting such preventive treatment.

Conclusions:

• The World Health Organization has updated its TB preventive treatment guidelines, strongly recommending a six-month course of levofloxacin for MDR-TB exposed contacts.
• The development of novel, shorter treatment regimens holds promise for the future management of MDR-TB infection, pending demonstration of safety and efficacy.